非酒精性脂肪性肝病心血管疾病风险与预期寿命损失
发生非致死性心血管疾病后,NAFLD患者与对照的全因死亡风险相似;NAFLD患者预期寿命平均较对照低2.8年。
要点
- NAFLD患者心血管疾病风险约为对照的2.6倍(aHR=2.61)。
- 非致死性心血管疾病风险在NAFLD患者中约为对照的3.7倍(aHR=3.71)。
- NAFLD患者预期寿命平均较对照低2.8年,中年诊断者损失最大。
核心结论
- NAFLD与较高的非致死性心血管疾病风险相关,但不影响心血管疾病事件后的死亡风险。
- NAFLD患者预期寿命低于一般人群。
研究设计与样本
- 采用多状态模型和灵活参数生存模型估计调整风险比和预期寿命损失。
主要发现
- NAFLD患者中识别出1037例(10.3%)心血管疾病事件,对照中为4041例(4.2%)。
- NAFLD患者心血管疾病风险约为对照的2.6倍(aHR=2.61,95%CI=2.36-2.88)。
- 非致死性心血管疾病风险在NAFLD患者中约为对照的3.7倍(aHR=3.71,95%CI=3.29-4.17)。
- 发生非致死性心血管疾病事件后,NAFLD患者与对照的全因死亡风险相似(aHR=0.89,95%CI=0.64-1.25)。
- NAFLD患者预期寿命平均较对照低2.8年,中年(40-60岁)诊断时损失生命年最多。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Conflicting evidence exists on cardiovascular disease (CVD) risk in patients with NAFLD, and data are lacking on whether NAFLD increases mortality after a CVD event. Moreover, life expectancy in NAFLD has not been studied. We therefore examined CVD risk and life expectancy in patients with NAFLD compared with the general population. APPROACH AND RESULTS: In this nationwide population-based cohort, all patients with NAFLD diagnosis and without baseline CVD (ascertaining from the Swedish National Patient Register from 1987 to 2016, n = 10,023) were matched 10:1 on age, sex, and municipality to individuals from the general population (controls, n = 96,313). CVD diagnosis and mortality were derived from national registers. Multistate models and flexible parametric survival models were used to estimate adjusted hazard ratios (aHRs) for CVD risk and loss in life expectancy due to NAFLD. We identified 1037 (10.3%) CVD events in patients with NAFLD and 4041 (4.2%) in controls. CVD risk was 2.6-fold higher in NAFLD compared with controls (aHR = 2.61, 95% CI = 2.36-2.88) and was strongest for nonfatal CVD (aHR = 3.71, 95% CI = 3.29-4.17). After a nonfatal CVD event, the risk for all-cause mortality was similar between patients with NAFLD and controls (aHR = 0.89, 95% CI = 0.64-1.25). Life expectancy in patients with NAFLD was, on average, 2.8 years lower than controls, with the highest loss of life-years when NAFLD was diagnosed in middle age (40-60 years). CONCLUSIONS: NAFLD was associated with a higher risk of nonfatal CVD but did not affect post-CVD mortality risk. Patients diagnosed with NAFLD have a lower life expectancy than the general population.
引用
- Shang Y, Nasr P, Widman L, et al. Risk of cardiovascular disease and loss in life expectancy in NAFLD. Hepatology. 2022. PMID: 35403232. doi:10.1002/hep.32519
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。